SWL-1 Reverses Fluconazole Resistance in Candida albicans by Regulating the Glycolytic Pathway
Open Access
- 16 October 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11, 572608
Abstract
C. albicans is a ubiquitous clinical fungal pathogen. Prolonged use of the first-line antifungal agent fluconazole has intensified fungal resistance and limited its effectiveness for the treatment of fungal infections. The combined administration of drugs has been extensively studied and applied. SWL-1 is a lignin compound derived from the Traditional Chinese Medicine Schisandra chinensis. In this study, we show that SWL-1 reverses resistance to fluconazole in C. albicans when delivered in combination, with a sharp decrease in the IC50 of fluconazole from >200 µg/mL to 3.74±0.25 µg/mL, and also reverses the fluconazole resistance of C. albicans in vitro, with IC50 from >200 to 5.3±0.3 µg/mL. Moreover, killing kinetics curves confirmed the synergistic effects of fluconazole and SWL-1. Intriguingly, when SWL-1 was administered in combination with fluconazole in a mouse model of systemic infection, the mortality of mice was markedly decreased and fungal colonization of the kidney and lung was reduced. Further mechanistic studies showed that SWL-1 significantly decreased intracellular ATP levels and inhibited the function of the efflux pump responsible for fluconazole resistance of C. albicans. Proteomic analysis of the effects of SWL-1 on C. albicans showed that several enzymes were downregulated in the glycolytic pathway. We speculate that SWL-1 significantly decreased intracellular ATP levels by hindering the glycolysis, and the function of the efflux pump responsible for fluconazole resistance of C. albicans was inhibited,so the fluconazole sensitive of FLC-resistant C. albicans was restored. This study clarified the effects and mechanism of SWL-1 on C. albicans in vitro and in vivo, providing a novel approach to overcoming fungal resistance.Keywords
Funding Information
- National Natural Science Foundation of China (81660737, 81422046, 21762048)
- Applied Basic Research Foundation of Yunnan Province (2017FF117-003, 2015FB205-023, 2018FY001, 2018FA048)
This publication has 31 references indexed in Scilit:
- Efflux pump proteins in antifungal resistanceFrontiers in Pharmacology, 2014
- CX3CR1-dependent renal macrophage survival promotes Candida control and host survivalJournal of Clinical Investigation, 2013
- Metabolic Pathways in Immune Cell Activation and QuiescenceImmunity, 2013
- Six new lignans from the leaves and stems of Schisandra sphenantheraFitoterapia, 2013
- Transcriptional Regulation of Carbohydrate Metabolism in the Human Pathogen Candida albicansPLOS Pathogens, 2009
- Efflux-Mediated Antifungal Drug ResistanceClinical Microbiology Reviews, 2009
- Potent In Vitro Synergism of Fluconazole and Berberine Chloride against Clinical Isolates of Candida albicans Resistant to FluconazoleAntimicrobial Agents and Chemotherapy, 2006
- Synergy, antagonism, and what the chequerboard puts between themJournal of Antimicrobial Chemotherapy, 2003
- Antifungal Resistance Trends Towards the Year 2000Drugs, 1997
- The constituents of Schizandra chinensis Baill. VII. The structures of three new lignans, (-)-gomisin K1 and (+)-gomisins K2 and K3.Chemical and Pharmaceutical Bulletin, 1980